Ruboxistaurin

Ruboxistaurin is a protein kinase C inhibitor that was developed by Eli Lilly and Company. It was primarily investigated for its potential use in the treatment of diabetic retinopathy and diabetic neuropathy, but it has not been approved by the Food and Drug Administration (FDA) for these indications.

History

Ruboxistaurin, also known as LY333531, was first synthesized by researchers at Eli Lilly and Company in the late 1990s. The compound was developed as a selective inhibitor of protein kinase C beta, an enzyme that is implicated in the development of several complications of diabetes.

Mechanism of Action

Ruboxistaurin inhibits protein kinase C beta, an enzyme that is overactive in people with diabetes. This enzyme is involved in the regulation of blood flow and nerve function, and its overactivity can lead to the development of diabetic retinopathy and neuropathy. By inhibiting this enzyme, ruboxistaurin may help to prevent or slow the progression of these conditions.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of ruboxistaurin in the treatment of diabetic retinopathy and neuropathy. While some studies have shown promising results, the drug has not been approved by the FDA for these indications.

Potential Uses

In addition to its potential use in the treatment of diabetic retinopathy and neuropathy, ruboxistaurin has also been investigated for its potential use in the treatment of other conditions, including cancer, cardiovascular disease, and Alzheimer's disease. However, further research is needed to determine the safety and efficacy of ruboxistaurin in these settings.

See Also

• Protein kinase C
• Diabetic retinopathy
• Diabetic neuropathy
• Eli Lilly and Company

‎